multiple dose studies [Design Issues]

posted by Loky do – Egypt, 2024-03-11 12:20 (478 d 13:59 ago) – Posting: # 23900
Views: 3,279

❝ As this is FDC- both the drug needs to be analyzed and thus also consider Solifenacin for washout consideration.

I'm a little confused :confused: why to analyze solifenacin as it is immediate release and the concern towards tamsulosin as it is the delayed release one, even if I took into consideration the washout of both, are the results of solifenacin, in this case, affect those of tamsulosin?

Regards,
Loky

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,425 posts in 4,928 threads, 1,682 registered users;
54 visitors (0 registered, 54 guests [including 11 identified bots]).
Forum time: 03:20 CEST (Europe/Vienna)

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5